MCID: LNG044
MIFTS: 67

Long Qt Syndrome 1 malady

Categories: Genetic diseases, Rare diseases, Cardiovascular diseases

Aliases & Classifications for Long Qt Syndrome 1

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 35LifeMap Discovery®, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Long Qt Syndrome 1:

Name: Long Qt Syndrome 1 52 48 24 70 27 35
Romano-Ward Syndrome 11 48 25 54 70 50 39 68
Long Qt Syndrome 11 23 48 24 50 39 13 68
Ward-Romano Syndrome 48 24 25 70
Lqt1 48 24 70
Rws 24 25 70
Romano-Ward Long Qt Syndrome 24 54
Romano Ward Syndrome 24 27
 
Long Q-T Syndrome 11 27
Ventricular Fibrillation with Prolonged Qt Interval 48
Long Qt Syndrome, Autosomal Dominant 24
Long Qt Syndrome 1, Acquired 52
Long Qt Syndrome-1 12
Lqt 1 24
Wrs 25
Lqt 11

Characteristics:

Orphanet epidemiological data:

54
romano-ward syndrome:
Inheritance: Autosomal dominant; Prevalence: 1-5/10000 (Europe); Age of onset: All ages

HPO:

64
long qt syndrome 1:
Inheritance: autosomal dominant inheritance, heterogeneous

GeneReviews:

23
Penetrance: lqts exhibits reduced penetrance of the ecg changes and symptoms. overall, approximately 25% of individuals with a pathogenic variant have a normal qtc (defined as <440 msec) on baseline ecg. the percentage of genetically affected individuals with a normal qtc was higher in the lqts type 1 group (36%) than in the lqts type 2 group (19%) or the type 3 group (10%) [priori et al 2003, goldenberg et al 2011]...


Classifications:



External Ids:

OMIM52 192500
Disease Ontology11 DOID:2843
ICD1030 I45.81
ICD9CM32 426.82
Orphanet54 ORPHA101016
UMLS via Orphanet69 C0035828
MESH via Orphanet40 D029597
ICD10 via Orphanet31 I45.8

Summaries for Long Qt Syndrome 1

About this section
OMIM:52 Congenital long QT syndrome is electrocardiographically characterized by a prolonged QT interval and polymorphic... (192500) more...

MalaCards based summary: Long Qt Syndrome 1, also known as romano-ward syndrome, is related to long qt syndrome 9 and long qt syndrome 14, and has symptoms including abnormality of the ear, syncope and sudden cardiac death. An important gene associated with Long Qt Syndrome 1 is KCNQ1 (Potassium Voltage-Gated Channel Subfamily Q Member 1), and among its related pathways are RHO GTPases activate IQGAPs and Interaction between L1 and Ankyrins. Affiliated tissues include heart, testes and skin, and related mouse phenotypes are cardiovascular system and muscle.

Disease Ontology:11 An autosomal genetic disease that is characterized by delayed repolarization of the heart following a heartbeat increases the risk of episodes of torsade de pointes (TDP, a form of irregular heartbeat that originates from the ventricles).

Genetics Home Reference:25 Romano-Ward syndrome is a condition that causes a disruption of the heart's normal rhythm (arrhythmia). This disorder is a form of long QT syndrome, which is a heart condition that causes the heart (cardiac) muscle to take longer than usual to recharge between beats. The irregular heartbeats can lead to fainting (syncope) or cardiac arrest and sudden death.

NIH Rare Diseases:48 Long QT syndrome is a disorder of the heart’s electrical activity that can cause sudden, uncontrollable, and irregular heartbeats (arrhythmia), which may lead to sudden death. Long QT syndrome can be detected by electrocardiogram (EKG). It can be caused by a variety of different gene mutations (changes). It can also be acquired (noninherited) and may be brought on by certain medicines and other medical conditions. Last updated: 10/4/2013

UniProtKB/Swiss-Prot:70 Long QT syndrome 1: A heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress, and can present with a sentinel event of sudden cardiac death in infancy.

Wikipedia:71 Long QT syndrome (LQTS) is a rare congenital and inherited or acquired heart condition in which delayed... more...

GeneReviews for NBK1129

Related Diseases for Long Qt Syndrome 1

About this section

Diseases in the Long Qt Syndrome-3 family:

Long Qt Syndrome 15 Long Qt Syndrome 9
Long Qt Syndrome-11 Long Qt Syndrome 2
long qt syndrome 1 Long Qt Syndrome-10
Long Qt Syndrome 13 Long Qt Syndrome 14
Long Qt Syndrome 12 Long Qt Syndrome 6
Long Qt Syndrome 5 Familial Long Qt Syndrome

Diseases related to Long Qt Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 117)
idRelated DiseaseScoreTop Affiliating Genes
1long qt syndrome 934.9CAV3, KCNJ2
2long qt syndrome 1434.7CALM1, CALM2
3long qt syndrome 1534.6CALM1, CALM2
4jervell and lange-nielsen syndrome32.7AKAP9, ANK2, CALM1, CALM2, CAV3, KCNE1
5sudden infant death syndrome30.7CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1
6long qt syndrome 212.6
7long qt syndrome 512.5
8long qt syndrome 1312.4
9long qt syndrome 612.4
10long qt syndrome 1212.4
11familial long qt syndrome12.2
12scn5a-related romano ward syndrome12.2
13timothy syndrome12.1
14andersen syndrome12.1
15long qt syndrome-311.8
16cardiac arrhythmia, ankyrin-b-related11.8
17long qt syndrome-1111.8
18long qt syndrome-1011.7
19wolcott-rallison syndrome11.2
20ragweed sensitivity11.0
21andersen syndrome type 111.0
22parkinson disease 20, early-onset10.9KCNE1, KCNH2
23carotid stenosis10.8CALM1, CALM2
24acute tricyclic antidepressant poisoning10.8KCNH2, KCNJ2, KCNQ1
25brugada syndrome 110.8CACNA1C, KCNH2, SCN5A
26ventricular fibrillation, familial, 110.8CACNA1C, RYR2, SCN5A
27ventricular tachycardia, catecholaminergic polymorphic, 110.8ANK2, CALM1, RYR2
28ciliary dyskinesia, primary, 9, with or without situs inversus10.8KCNE2, KCNJ2, KCNJ5
29bleeding disorder, platelet-type, 1510.8CALM1, CALM2
30submucous uterine fibroid10.7CACNA1C, KCND3, SCN5A
31porokeratosis10.7CALM1, CALM2
32second-degree atrioventricular block10.7KCNE1, KCNE2, KCNH2, KCNQ1, SCN5A
33todd's paralysis10.7CALM1, CALM2, KCNH2, KCNQ1, SCN5A
34frontotemporal dementia, right temporal atrophy variant10.7DSP, RYR2
35cardiac conduction disease with or without dilated cardiomyopathy10.7ANK2, KCNE2, KCNH2, KCNJ2, KCNQ1
36usher syndrome10.7DSP, KCNH2, RYR2
37brugada syndrome 310.7CACNA1C, KCNE1, KCNH2, KCNQ1, SCN4B
38fixed pigmented erythema10.7DSP, RYR2
39ectodermal dysplasia10.7DSP, KCNH2, RYR2, SCN5A
40regional ureteric cancer10.7CALM1, CALM2
41ketamine-induced biliary dilatation10.7DSP, RYR2
42prostate malignant phyllodes tumor10.6KCND3, KCNE1, KCNH2, KCNQ1, RYR2, SCN5A
43meningitis10.6CALM1, CALM2
44adams-oliver syndrome10.6ANK2, KCNE2, KCNJ2, KCNQ1, SCN4B, SCN5A
45cerebral cavernous malformation, familial10.6ANK2, CALM1, CALM2, KCNH2, KCNJ2, RYR2
46umbilical hernia10.6CALM1, CALM2, DSP, KCNQ1, RYR2, SCN5A
47cardiovascular disease risk factor )10.6CACNA1C, CAV3, DSP, RYR2, SCN5A
48pontiac fever10.6CALM1, CALM2
49sult4a1-related altered drug metabolism10.5CALM1, CALM2, KCNE1, KCNE2, KCNH2, KCNQ1
50atrial fibrillation, familial, 310.5CACNA1C, CAV3, KCNE1, KCNE2, KCNH2, KCNQ1

Graphical network of the top 20 diseases related to Long Qt Syndrome 1:



Diseases related to long qt syndrome 1

Symptoms & Phenotypes for Long Qt Syndrome 1

About this section

Symptoms by clinical synopsis from OMIM:

192500

Clinical features from OMIM:

192500

Human phenotypes related to Long Qt Syndrome 1:

 64 (show all 6)
id Description HPO Frequency HPO Source Accession
1 abnormality of the ear64 HP:0000598
2 syncope64 HP:0001279
3 sudden cardiac death64 HP:0001645
4 prolonged qt interval64 HP:0001657
5 ventricular fibrillation64 HP:0001663
6 torsade de pointes64 HP:0001664

UMLS symptoms related to Long Qt Syndrome 1:


syncope

MGI Mouse Phenotypes related to Long Qt Syndrome 1 according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538510.3CACNA1C, CAV3, DSP, KCND3, KCNH2, KCNJ2
2MP:00053699.6CACNA1C, CAV3, DSP, KCNH2, KCNJ2, KCNQ1

Drugs & Therapeutics for Long Qt Syndrome 1

About this section

Drugs for Long Qt Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 201)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
MethadoneapprovedPhase 4, Phase 131976-99-34095
Synonyms:
(+)-Methadone
(+-)-Methadone
(+/-)-Methadone
(+/-)-Methadone hydrochloride
(+/-)-Tussal
(-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
(-)-Methadone
(6R)-Methadone
(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
(R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone
(S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
(±)-methadone
1095-90-5 (hydrochloride)
297-88-1
3-14-00-00278 (Beilstein Handbook Reference)
3-14-00-00279 (Beilstein Handbook Reference)
3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)- (9CI)
5653-80-5
6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture
6-(dimethylamino)-4,4-diphenylheptan-3-one
6-Dimethylamino-4,4-diphenyl-3-heptanone
6-dimethylamino-4,4-di(phenyl)heptan-3-one
6S-Methadone
76-99-3
A 4624
AC-16055
AC1L1HEG
AC1Q2RLW
AN 148
AN-148 (*Hydrochloride*)
Adanon
Adanon hydrochloride
Adolan
Algidon
Algolysin
Algovetin
Althose
Althose hydrochloride
Amidon
Amidone
BRN 3213667
BRN 3213668
BRN 3213669
Biscuits
Butalgin
C07163
CHEBI:6807
CHEMBL651
CID4095
D08195
DB00333
DEA No. 9250
DL-Methadone hydrochloride
Depridol
Dextromethadone
Diaminon
Diaminon hydrochloride
DivK1c_000963
Dl-Methadone
Dollies
Dolly
Dolofin hydrochloride
Dolohepton
Dolophin
Dolophin hydrochloride
Dolophine
Dolophine (*Hydrochloride*)
Dolophine HCL
EINECS 200-996-9
Fenadon
Fenadone
 
Fenadone (*Hydrochloride*)
HSDB 3119
Heptadon
Heptadone
Heptadone (*Hydrochloride*)
Heptanon
Heptanon (*Hydrochloride*)
Heptanon (pharmaceutical)
Hoechst 10820
Hoescht 10820 (*Hydrochloride*)
IDI1_000963
K 174
KBio1_000963
Ketalgin
Ketalgin hydrochloride
L-(+)-Methadone
L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
L-Polamidon
L000874
LS-74485
LS-74486
LS-74487
Levometadona
Levometadona [INN-Spanish]
Levomethadone [INN]
Levomethadonum
Levomethadonum [INN-Latin]
Levothyl
Mecodin
Mephenon
Metadona
Metadona [INN-Spanish]
Metadona [Spanish]
Metadone
Metadone [DCIT]
Metasedin
Methadon
Methadona
Methadona [Spanish]
Methadone (BAN)
Methadone HCL
Methadone HCL Intensol
Methadone M
Methadone [INN:BAN]
Methadone hydrochloride
Methadonum
Methadonum [INN-Latin]
Methadonum [Latin]
Methadose
Methaquaione
Miadone
Moheptan
MolPort-001-785-650
NINDS_000963
Phenadone
Phenadone (*Hydrochloride*)
Phenadone hydrochloride
Physeptone
Polamidon
Polamidone
Polamivet
Racemic methadone
S-(+)-Methadone
Sedo-Rapide
Tussol
UNII-UC6VBE7V1Z
Westadone
d-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
d-Methadone
dl-Methadone
l-Methadone
l-Polamivet
methadone
2
Estradiolapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1128350-28-25757, 53477783
Synonyms:
(+)-3,17b-Estradiol
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17beta)-Estra-1,3,5(10)-triene-3,17-diol
.alpha.-Estradiol
.alpha.-Oestradiol
.beta.-Estradiol
.beta.-Oestradiol
1,3,5[10]-Estratriene-3,17beta-diol 3-sulfate
1,3,5[10]-Estratriene-3,17beta-diol 3-sulphate
13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol
17 beta-Estradiol
17-.BETA.-Estradiol
17-E
17-beta
17-beta-OH-estradiol
17-beta-estradiol
17.beta.-Estradiol
17.beta.-Oestradiol
17E
17b-Estradiol
17b-Oestradiol
17beta Oestradiol
17beta oestradiol
17beta-Estra-1,3,5(10)-triene-3,17-diol
17beta-Estradiol
17beta-Oestradiol
1jgl
1qkt
1qku
2d06
3,17-Epidihydroxyestratriene
3,17-beta-Estradiol
3,17-beta-Oestradiol
3,17.beta.-Estradiol
3,17b-Dihydroxyestra-1,3,5(10)-triene
3,17b-Estradiol
3,17beta-Estradiol
3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulfate
3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulphate
50-28-2
73459-61-7
873662-39-6
AC-10460
AC1L1L2K
Aerodiol
Agofollin
Alora
Altrad
Amnestrogen
Aquadiol
B-Estradiol
BEDOs
BIDD:ER0125
BIDD:PXR0065
BPBio1_000532
BSPBio_000482
BSPBio_001065
Bardiol
Benzhormovarine
Beta-estradiol
Bio-0812
Bio-E-Gel
Bio1_000403
Bio1_000892
Bio1_001381
Bio2_000363
Bio2_000843
C00951
C18H24O2
CCRIS 280
CHEBI:16469
CHEMBL135
CID5757
CMC_11154
CPD-352
CPD000059126
Climaderm
Climara
Climara (TN)
Climara Forte
Compudose
Compudose 200
Compudose 365
Corpagen
D-3,17beta-Estradiol
D-Estradiol
D-Oestradiol
D00105
DB00783
Dermestril
Destradiol
Dihydro-Theelin
Dihydrofollicular hormone
Dihydrofolliculin
Dihydromenformon
Dihydrotheelin
Dihydroxyesterin
Dihydroxyestrin
Dihydroxyoestrin
Dimenformon
Diogyn
Diogynets
Divigel
Divigel (TN)
E 2
E 8875
E(sub 2)
E0025
E1024_SIGMA
E1132_SIGMA
E2257_SIGMA
E2758_SIGMA
E8875_SIGMA
EINECS 200-023-8
EU-0100503
Elestrin
Encore
Epiestriol 50
Esclim
Estra-1,3,5(10)-triene-3,17b-diol
Estrace
Estrace (TN)
Estraderm
Estraderm (TN)
Estraderm MX
Estraderm TTS
Estraderm TTS 100
Estraderm TTS 50
Estradiol
Estradiol [USAN:INN]
Estradiol-17 beta
Estradiol-17-beta
Estradiol-17.beta.
Estradiol-17beta
Estradiol-3,17beta
Estradiolo
Estradiolo [DCIT]
Estradiolum
Estradiolum [INN]
Estradot
Estraldine
Estrapak 50
Estrasorb
Estrasorb (TN)
Estreva
Estrifam
Estring
Estring (TN)
Estring Vaginal Ring
Estring vaginal ring
Estroclim
Estroclim 50
Estrodiolum
Estrofem 2
Estrofem Forte
Estrogel
 
Estrogel (TN)
Estrogel HBF
Estrovite
Evamist
Evorel
Extrasorb
Femanest
Femestral
Femestrol
Femogen
Fempatch
Femtrace
Femtran
Follicyclin
Gelestra
Ginedisc
Ginosedol
GynPolar
Gynergon
Gynestrel
Gynodiol
Gynoestryl
HMS1362E07
HMS1569I04
HMS1792E07
HMS1990E07
HMS2051C17
HMS2090E18
HSDB 3589
IDI1_002118
Innofem
Innofem (TN)
KBio2_000405
KBio2_002269
KBio2_002973
KBio2_004837
KBio2_005541
KBio2_007405
KBio3_000769
KBio3_000770
KBio3_002749
KBioGR_000405
KBioGR_002269
KBioSS_000405
KBioSS_002270
LMST02010001
LS-137
Lamdiol
Lio-Oid
Lopac0_000503
MLS000069494
MLS000758312
MLS001076331
Macrodiol
Macrol
Menest
Menorest
Menostar
Microdiol
MolPort-001-794-632
NCGC00091544-00
NCGC00091544-01
NCGC00091544-02
NCGC00091544-04
NCGC00091544-05
NCGC00091544-06
NCGC00091544-07
NCGC00091544-08
NCGC00091544-09
NCGC00091544-12
NCGC00179321-01
NCGC00179321-02
NSC-9895
NSC9895
Nordicol
Oesclim
Oestergon
Oestra-1,3,5(10)-triene-3,17b-diol
Oestradiol
Oestradiol Berco
Oestradiol R
Oestradiol-17-beta
Oestradiol-17.beta.
Oestradiol-17beta
Oestradiolum
Oestrogel
Oestroglandol
Oestrogynal
Ovahormon
Ovasterol
Ovastevol
Ovociclina
Ovocyclin
Ovocycline
Ovocylin
Perlatanol
Polyestradiol
Prestwick0_000441
Prestwick1_000441
Prestwick2_000441
Prestwick3_000441
Prestwick_207
Primofol
Profoliol
Profoliol B
Progynon
Progynon DH
Progynon-DH
S-21400
S1709_Selleck
SAM001247032
SK-Estrogens
SL-1100
SMP1_000121
SMR000059126
SPBio_002421
Sandrena 1
Sandrena Gel
Sisare Gel
Spectrum5_002055
Syndiol
Systen
Tradelia
Trial SAT
Trocosone
UNII-4TI98Z838E
VIVELLE-DOT
Vagifem
Vagifem (TN)
Vivelle
Vivelle (TN)
Zerella
Zesteem
Zesteen
Zumenon
[2,4,6,7-3H]-E2
[3H]-estradiol
[3H]]estradiol
b-Estradiol
beta-Estradiol
beta-Estradiol 3-sulfate
beta-Estradiol 3-sulphate
bmse000642
cMAP_000005
cis-Estradiol
cis-Oestradiol
component of Menrium
delta-Estradiol
delta-Oestradiol
estradiol
estradiol-17beta
nchembio.168-comp3
nchembio.76-comp2
nchembio775-comp2
nchembio794-comp6
nchembio860-comp1
progynon
3
Ethinyl EstradiolapprovedPhase 4, Phase 2, Phase 3, Phase 171257-63-65991
Synonyms:
17 alpha-Ethinylestradiol
17 alpha-Ethynylestradiol
17 alpha-Ethynyloestradiol
17 alpha-ethinyestradiol
17-Ethinyl-3,17-estradiol
17-Ethinyl-3,17-oestradiol
17-Ethinylestradiol
17-Ethynylestradiol
17-Ethynylestradiol ram
17-Ethynyloestradiol
17-alpha-Ethinyl-17-beta-estradiol
17-alpha-Ethynyl-17-beta-oestradiol
17-alpha-Ethynylestradiol
17-alpha-Ethynylestradiol-17-beta
17-alpha-ethynyl estradiol
17-ethinyl-3,17-estradiol
17-ethinyl-3,17-oestradiol
17-ethinylestradiol
17.alpha.-Ethinyl-17.beta.-estradiol
17.alpha.-Ethinylestradiol
17.alpha.-Ethynyl-17.beta.-oestradiol
17.alpha.-Ethynylestradiol
17.alpha.-Ethynylestradiol-l7.beta.
17.alpha.-Ethynyloestradiol
17.alpha.-Ethynyloestradiol-17.beta.
17a-Ethinyl-17b-estradiol
17a-Ethinylestradiol
17a-Ethynyl-17b-oestradiol
17a-Ethynylestradiol
17a-Ethynylestradiol-l7b
17a-Ethynyloestradiol
17a-Ethynyloestradiol-17b
17alpha-Ethinyl estradiol
17alpha-Ethinylestradiol
17alpha-Ethinylestradiol-17beta
17alpha-Ethynylestradiol
17alpha-Ethynyloestradiol
17alpha-Ethynyloestradiol-17beta
17α-ethynylestradiol
406932-93-2
46263_FLUKA
46263_RIEDEL
57-63-6
77538-56-8
AC-2169
AC1L1LK6
AI3-52941
Aethinyloestradiolum
Aethinyoestradiol
Aethinyoestradiol [German]
Alora
Amenoron
Amenorone
Anovlar
BIDD:ER0162
BRN 2419975
Bio-0610
C07534
CCRIS 286
CHEBI:4903
CHEMBL691
CID5991
CPD000058319
Certostat
Chee-O-Gen
Chee-O-Genf
Cyclosa
D004997
D00554
DB00977
Dicromil
Diognat-E
Diogyn E
Diogyn-E
Diprol
Dyloform
E4876_SIGMA
EE
EE(sub 2)
EE2
EINECS 200-342-2
EO
ETHINYLESTRADIOL
Effik Brand of Ethinyl Estradiol
Ertonyl
Esclim
Esteed
Estigyn
Estinyl
Estinyl (TN)
Eston-E
Estopherol
Estoral
Estoral (Orion)
Estoral (VAN)
Estoral [Orion]
Estoral {[Orion]}
Estorals
Estradiol, Ethinyl
Estradiol, Ethynyl
Estring
Estrogen
Ethidol
Ethinoral
Ethinyl E2
Ethinyl Estradiol Hemihydrate
Ethinyl Estradiol [USP]
 
Ethinyl Estradiol, (8 alpha)-Isomer
Ethinyl Oestradiol Effik
Ethinyl estradiol
Ethinyl estradiol (USP)
Ethinyl-Oestradiol Effik
Ethinyl-Oestranol
Ethinyl-oestranol
Ethinylestradiol
Ethinylestradiol (JP15/INN)
Ethinylestradiol Jenapharm
Ethinylestradiol [INN:BAN:JAN]
Ethinylestradiolum
Ethinylestradiolum [INN-Latin]
Ethinylestriol
Ethinyloestradiol
Ethinyloestradiol [Steroidal oestrogens]
Ethy 11
Ethynyl estradiol
Ethynylestradiol
Ethynylestradiol, Ethinyl Estradiol
Ethynyloestradiol
Eticyclin
Eticyclol
Eticylol
Etinestrol
Etinestryl
Etinilestradiol
Etinilestradiol [INN-Spanish]
Etinilestradiolo
Etinilestradiolo [DCIT]
Etinoestryl
Etistradiol
Etivex
Evra
Feminone
Fempatch
Follicoral
Ginestrene
Gynodiol
Gynolett
HMS2051I19
HSDB 3587
Halodrin
Hemihydrate, Ethinyl Estradiol
Inestra
Innofem
Jenapharm Brand of Ethinyl Estradiol
Jenapharm, Ethinylestradiol
Kolpolyn
LMST02010036
LS-231
Linoral
Lynoral
MLS000028479
MLS000758274
Marvelon
Menolyn
Menostar
Mercilon
Microfollin
Microfollin Forte
MolPort-001-794-636
NCGC00091533-01
NCGC00091533-04
NCGC00091533-05
NCI60_000234
NSC-10973
NSC10973
Neo-Estrone
Nogest-S
Novestrol
OVULEN-21
OVULEN-28
Oradiol
Orestralyn
Orestrayln
Organon Brand of Ethinyl Estradiol
Ortho-Cyclen
Ovex
Oviol
PUBERTAL ETHINYL ESTRADIOL STUDY
Palonyl
Perovex
Primogyn
Primogyn C
Primogyn M
Progynon C
Progynon M
Prosexol
S1625_Selleck
SAM001247008
SGCUT00127
SMR000058319
Schering Brand of Ethinyl Estradiol
Spanestrin
Thiuram E
Thiuranide
UNII-423D2T571U
Vagifem
Varnoline
WLN: L E5 B666TTT&J E1 FQ F1UU1 OQ
Ylestrol
component of Demulen
component of Oracon
component of Ortrel
ethinyl estradiol
ethynyl estradiol
to_000048
4
NorgestimateapprovedPhase 4, Phase 2, Phase 3, Phase 138135189-28-76540478
Synonyms:
(+)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester)
(17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime
(17alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime
(3E)-17alpha-ethynyl-3-(hydroxyimino)-18a-homoestr-4-en-17beta-yl acetate
35189-28-7
AC-655
AC1O712U
C017576
CHEBI:50815
CHEMBL1200934
CID6540478
D 138
D-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-one oxime
D05209
DB00957
Dexnorgestrel Acetime
Dexnorgestrel acetime
I14-9729
 
LS-62080
NCGC00181353-01
NORGESTIMATE
Norgestimate (USP/INN)
Norgestimate [USAN:INN:BAN]
Norgestimato
Norgestimato [INN-Spanish]
Norgestimatum
Norgestimatum [INN-Latin]
ORF 10131
ORF-10131
Ortho-Prefest
RWJ 10131
RWJ-10131
UNII-C291HFX4DY
ZINC03938695
[(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
d-13-beta-Ethyl-17-alpha-ethynyl-17-beta-acetoxygon-4-en-3-one oxime
d-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-one oxime
norgestrel oxime acetate
5
Guaifenesinapproved, vet_approvedPhase 4, Phase 161693-14-13516
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
Amonidren
Amonidrin
Aresol
Benylin-E
Bronchol
Glycerin ether
Glycerin guaiacolate
Glycero-guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
Glyceryl guiacolate
 
Glycerylguaiacol
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesin
Guaifenesine
Guaiphenesin
Guaiphenesine
Guaiphesin
Hustosil
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
O-Methoxyphenyl glyceryl ether
Organidin NR
Pneumomist
Propanosedyl
Reduton
Robitussin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
guaiphenesin
p-Cresyl acetate
6
Moxifloxacinapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1427354812-41-2, 151096-09-2152946
Synonyms:
(1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
151096-09-2
186826-86-8
192927-63-2
7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
AC1L49EP
Actira (*Hydrochloride*)
Avelox
Avelox (*Hydrochloride*)
Avelox I.V.
BAY 12-8039
 
BAY 12-8039 (*Hydrochloride*)
CCRIS 8690
CHEMBL32
CID152946
DB00218
I06-1961
LS-141510
MFX
MXF
MXFX
Moxifloxacin [INN:BAN]
UNII-U188XYD42P
Vigamox
moxifloxacin
7
IbutilideapprovedPhase 4, Phase 25122647-32-9, 122647-31-860753
Synonyms:
(+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfoanilide (E)-2-butenedioate (2:1)
(+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfonanilide fumarate (2:1) (salt)
(+-)-N-(4-(4-(Ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (E)-butenedioate
(E)-but-2-enedioic acid
122647-31-8
122647-31-8 (Parent)
122647-32-9
122647-32-9 (Fumarate)
130350-52-6
2C20H36N2O3S.C4H4O4
AC1L1TUW
AC1NQXZ2
AC1O5NJM
AC1Q6VUF
Butilide fumarate
C07753
C20H36N2O3S
CHEBI:112608
CHEMBL1200564
CHEMBL533
CID5281065
CID60753
CID6437366
Corvert
Corvert (TN)
D00648
D08060
DB00308
I06-1701
IBUTILIDE FUMARATE
Ibutilid
 
Ibutilida
Ibutilida [INN-Spanish]
Ibutilide
Ibutilide (INN)
Ibutilide Fumarate
Ibutilide Fumarate [USAN]
Ibutilide [BAN:INN]
Ibutilide [INN:BAN]
Ibutilide fumarate (USAN)
Ibutilidum
Ibutilidum [INN-Latin]
LS-172765
LS-90123
LS-90124
Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-, (E)-2-butenedioate (2:1) (salt)
Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-,(E)-2-butenedioate (2:1) (salt)
Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (E)-2-butenedioate (2:1) (salt)
MolPort-005-932-621
N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide
N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide
N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide
NCGC00181771-01
U 70226E
U-70226E
U-82208E
U-82209E
U82208E
U82209E
UNII-2436VX1U9B
UNII-9L5X4M5L6I
ibutilide, (+-)-isomer
ibutilide, fumarate salt (2:1), (+-)-isomer
n-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide
8
Aripiprazoleapproved, investigationalPhase 4, Phase 2353129722-12-960795
Synonyms:
129722-12-9
24-29-3
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
AC-1554
AC1L1TXZ
AC1Q3T38
ALKS-9070
Abilify
Abilify (TN)
Abilify Discmelt
Abilitat
Aripiprazol
Aripiprazole
Aripiprazole (JAN/USAN/INN)
Aripiprazole [USAN]
Aripiprazolum
Aripirazole
Arpizol
Asprito|
BMS-337039
Bio-0004
Bristol-Myers Squibb brand of aripiprazole
C094645
C12564
C23H27Cl2N3O2
CHEBI:31236
CHEMBL1112
CID60795
CPD000466383
 
D01164
DB01238
Discmelt
FT-0082572
HMS2051I18
HMS2089M20
HMS2093F22
HSDB 7320
KS-1030
L001339
LS-142666
MLS000759517
MLS001165779
MLS001195621
MLS001424078
MolPort-002-885-808
MolPort-003-844-657
NCGC00159510-02
NCGC00159510-03
OPC 31
OPC-14597
OPC-31
Opc 14597
Otsuka brand of aripiprazole
Pripiprazole
S06-0010
SAM001246750
SMR000466383
STK625160
TL8000707
TL80090184
UNII-82VFR53I78
aripiprazol
aripiprazole
aripiprazolum
||OPC 14597
9
Valproic Acidapproved, investigationalPhase 432299-66-13121
Synonyms:
(N-C3H7)2CHCOOH
(S)-2-propyl-4-pentanoate
(S)-2-propyl-4-pentanoic acid
2 PP (base)
2-N-Propyl-N-valeric acid
2-Propyl-Pentanoate
2-Propyl-Pentanoic acid
2-Propylpentanoate
2-Propylpentanoic Acid
2-Propylpentanoic acid
2-Propylvaleric Acid
2-Propylvaleric acid
2-n-Propyl-n-valeric acid
2-n-propyl-n-valeric acid
2-propyl-pentanoic acid
2-propylvaleric acid
4-Heptanecarboxylic acid
4-heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
AC1L1F7T
AC1Q2ULA
AI3-10500
APO-divalproex
Abbott 44090
Acide valproique
Acide valproique [INN-French]
Acide valproique [inn-french]
Acido valproico
Acido valproico [INN-Spanish]
Acido valproico [inn-spanish]
Acidum valproicum
Acidum valproicum [INN-Latin]
Acidum valproicum [inn-latin]
Alti-Valproic
Alti-valproic
Apo-valproic
Apo-valproic syrup
Avugane
BIDD:GT0858
BRN 1750447
Baceca
C07185
CHEBI:39867
CHEMBL109
CID3121
CPD000499581
Convulex
Convulsofin
D00399
DB00313
DOM-divalproex
DOM-valproic
DOM-valproic acid E.C.
DPA
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
Di-N-propylacetic acid
Di-N-propylessigsaure
Di-N-propylessigsaure [german]
Di-n-propylacetic acid
Di-n-propylessigsaeure
Di-n-propylessigsaure
Di-n-propylessigsaure [German]
Di-n-propylessigsäure
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
DivK1c_000273
Divalproex
Dom-Valproic
Dom-valproate
Dom-valproic acid
Dom-valproic acid syrup
EINECS 202-777-3
Epiject I.V.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
KBio2_004845
 
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
MLS001076682
MLS001335927
MLS001335928
MLS002415770
Med Valproic
Med valproic
MolPort-001-791-895
Mylproin
Myproate
Myproic Acid
Myproic acid
N-DPA
N-Dipropylacetic acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
NINDS_000273
NSC 93819
NSC93819
Novo-Valproic
Novo-Valproic - ECC
Novo-divalproex
Novo-valproic
Novo-valproic soft gel cap
Nu-Valproic
Nu-valproic
P0823
P6273_SIGMA
PEAC
PHL-valproate
PHL-valproic acid
PHL-valproic acid E.C.
PMS-Divalproex
PMS-Valproic Acid
PMS-valproate
PMS-valproic acid
PMS-valproic acid E.C.
Penta-Valproic
Penta-valproic
Propylvaleric acid
Ratio-Valproic - ECC
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
SBB065764
SMR000499581
SPBio_000912
Sandoz valproic
Savicol
Semisodium Valproate
Sodium hydrogen divalproate
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Spectrum_000521
Sprinkle
Stavzor
UNII-614OI1Z5WI
VALPROIC ACID
VPA
Valcote
Valparin
Valproate
Valproate semisodique [French]
Valproate semisodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
Valproic Acid, Sodium Salt (2:1)
Valproic acid
Valproic acid (USP)
Valproic acid USP
Valproic acid USP24
Valproic acid [USAN:INN:BAN]
Valproic acid [usan:ban:inn]
Valproinsaeure
Valproinsäure
Vupral
WLN: QVY3 & 3
acide valproïque
acidum valproicum
di-n-propylacetic acid
n-DPA
n-Dipropylacetic acid
nchembio.79-comp4
nchembio815-comp21
valproate
valproic acid
ácido valproico
10
Progesteroneapproved, vet_approvedPhase 4, Phase 253757-83-05994
Synonyms:
(S)-4-Pregnene-3,20-dione
(S)-Pregn-4-en-3,20-dione
(S)-Progesterone
.beta.-Progesterone
.delta.(sup4)-Pregnene-3,20-dione
.delta.4-Pregnene-3,20-dione
17.alpha.-Progesterone
17a-Progesterone
17alpha-Progesterone
17alpha-progesterone
17α-progesterone
1dbb
1h60
257630-50-5
3,20-Pregnene-4
32104FB6-BF81-4F6E-83C2-024DEEAEB272
4-Pregnen-3,20-dione
4-Pregnene-3,20-dione
46665_FLUKA
46665_RIEDEL
57-83-0
753497-20-0
8012-32-6
8023-13-0
AC-700
AC1L1LKF
AI3-51682
Agolutin
Akrolutin
BB_NC-0185
BHR-100
BIDD:ER0547
BIDD:PXR0094
BPBio1_000676
BRD-K64994968-001-03-6
BSPBio_000614
Bio-luton
C00410
CCRIS 533
CHEBI:17026
CHEMBL103
CID5994
CIDR
CMC_13406
COL-1620
CPD000058345
Colprosterone
Corlutin
Corlutina
Corluvite
Corporin
Corpus Luteum Hormone
Corpus luteum hormone
Crinone
Crinone (TN)
Crinone progesterone gel
Curretab
Cyclogest
Cyclogesterin
D00066
D4-Pregnene-3,20-dione
DB00396
DR-2011
Delalutin
Delta(4)-pregnene-3,20-dione
Duraprogen
EINECS 200-350-6
ETI-411
EU-0100895
Endometrin
Estima
FE-999913
Flavolutan
Fologenon
Gelbkoerperhormon
Gesterol
Gesterol 100
Gesterol 50
Gestiron
Gestone
Gestormone
Gestron
Glanducorpin
Gynlutin
Gynoluton
Gynolutone
HMS1569O16
HMS2051O05
HMS2090J07
HSDB 3389
Hormoflaveine
Hormoluton
Hydroxyprogesterone Caproate
Hydroxyprogesterone Caproic acid
LMST02030159
LS-234
Lingusorbs
Lipo-Lutin
Lipolutin
Lopac0_000895
Lucorteum
Lucorteum Sol
Lucorteum sol
Lugesteron
Luteal hormone
Luteinique
Luteocrin normale
Luteodyn
Luteogan
Luteohormone
Luteol
Luteol (VAN)
Luteopur
Luteosan
Luteostab
Luteovis
Luteum
Lutex
Lutidon
Lutin
Lutinus
Lutociclina
Lutocuclin M
Lutocyclin
Lutocyclin M
 
Lutocyclin m
Lutocylin
Lutocylol
Lutoform
Lutogyl
Lutogynon
Lutren
Lutromone
MLS000028517
MLS000758277
MLS001074187
MLS002222367
MPA
Membrettes
Methylpregnone
Micronized Progesterone
MolPort-001-794-643
NCGC00022185-03
NCGC00022185-04
NCGC00022185-05
NCGC00022185-06
NCGC00022185-07
NCGC00022185-08
NCGC00022185-09
NCGC00090798-01
NCGC00090798-02
NCI60_042166
NSC 64377
NSC 9704
NSC-9704
NSC64377
NSC9704
Nalutron
Natural Progesterone
P 0130
P0130_SIGMA
P0478
P3972_SIGMA
P6149_SIGMA
P7556_ALDRICH
P7556_SIGMA
P8783_SIGMA
P9776_SIGMA
PROGESTERONE
Percutacrine
Percutacrine Luteinique
Piaponon
Pranone
Pregn-4-en-3,20-dione
Pregn-4-ene-3,20-dione
Pregnene-3,20-dione
Pregnenedione
Prestwick0_000477
Prestwick1_000477
Prestwick2_000477
Prestwick3_000477
Prestwick_411
Primolut
Prochieve
Progeffik
Progekan
Progestan
Progestasert
Progesterol
Progesteron
Progesterona
Progesterona [INN-Spanish]
Progesterone
Progesterone (JP15/USP/INN)
Progesterone [INN:BAN:JAN]
Progesterone [Progestins]
Progesterone, water-soluble
Progesterone-Water Soluble
Progesterone: HBC complex
Progesteronum
Progesteronum [INN-Latin]
Progestin
Progestogel
Progestol
Progeston
Progestone
Progestosol
Progestrel
Progestron
Progestronol
Progestérone
Projestaject
Prolets
Prolidon
Prolutin
Proluton
Prolutone
Prometrium
Prometrium (TN)
Prontogest
Protormone
S00293
S1705_Selleck
SAM001247039
SMR000058345
SMR000653542
SPBio_002553
SR-01000000088
SR-01000000088-5
Spectrum5_002053
Syngesterone
Syngestrets
Synovex S
Syntolutan
U 3672
UNII-4G7DS2Q64Y
Utrogest
Utrogestan
Vitarrine
WLN: L E5 B666 OV MUTJ A1 E1 FV1
ZINC04428529
beta-Progesterone
bmse000482
component of Cyclogesterin
corpus luteum hormone
delta(4)-Pregnene-3,20-dione
delta(Sup 4)-Pregnene-3,20-dione
delta(Sup4)-pregnene-3,20-dione
delta(sup 4)-Pregnene-3,20-dione
delta4-Pregnene-3,20-dione
luteohormone
nchembio.2007.53-comp14
11
MethyltestosteroneapprovedPhase 454658-18-46010
Synonyms:
17(alpha)-Methyl-delta(4)-androsten-17(beta)-ol-3-one
17-Methyltestosterone
17-beta-Hydroxy-17-methylandrost-4-en-3-one
17-methyltestosterone
17alpha-Methyl-3-oxo-4-androsten-17beta-ol
17alpha-Methyl-delta(4)-androsten-17beta-ol-3-one
17alpha-Methyltestosterone
17alpha-methyl-delta-androsten-17beta-ol-3-one
17alpha-methyltestosterone
 
17beta-Hydroxy-17-methylandrost-4-en-3-one
17α-methyl-Δ4-androsten-17β-ol-3-one
17α-methyltestosterone
4-Androstene-17alpha-methyl-17beta-ol-3-one
Android
Methyltestosterone
Methyltestosteronum
Metiltestosterona
NSC-9701
Testred
Virilon
12
Testosteroneapproved, investigationalPhase 454658-22-06013
Synonyms:
(+)-testosterone
(+-)-8-iso-testosterone
(+-)-retrotestosterone
(+-)-testosterone
(17b)-17-hydroxy-androst-4-en-3-one
(17beta)-17-Hydroxyandrost-4-en-3-one
(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
13-Iso-testosterone
17-Hydroxy-(17-beta)-androst-4-en-3-one
17-Hydroxy-(17beta)-androst-4-en-3-one
17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one
17-Hydroxy-D4-androsten-3-one
17-Hydroxy-androst-4-en-3-one
17-beta-Hydroxy-delta(sup 4)-androsten-3-one
17-beta-Hydroxyandrost-4-en-3-one
17?-Hydroxy-4-androsten-3-one
17a-Hydroxy-(13a)-androst-4-en-3-one
17a-Hydroxy-13a-androst-4-en-3-one
17a-Hydroxy-14b-androst-4-en-3-one
17a-Hydroxy-androst-4-en-3-one
17b-Hydroxy-(10a)-androst-4-en-3-one
17b-Hydroxy-(13a)-androst-4-en-3-one
17b-Hydroxy-(8a)-androst-4-en-3-one
17b-Hydroxy-(8a,10a)-androst-4-en-3-one
17b-Hydroxy-(9b)-androst-4-en-3-one
17b-Hydroxy-(9b,10a)-androst-4-en-3-one
17b-Hydroxy-13a-androst-4-en-3-one
17b-Hydroxy-8a-androst-4-en-3-one
17b-Hydroxy-D4-androsten-3-one
17b-Hydroxy-androst-4-en-3-on
17b-Hydroxy-androst-4-en-3-one
17b-Hydroxyandrost-4-en-3-one
17b-Hydroxyandrost-4-ene-3-one
17b-Testosterone
17b-hydroxy-4-androsten-3-one
17beta-Hydroxy-3-oxo-4-androstene
17beta-Hydroxy-4-androsten-3-one
17beta-Hydroxy-delta(sup4)-androsten-3-one
17beta-Hydroxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-ene-3-one
17beta-hydroxy-4-androsten-3-one
4-Androsten-17?-ol-3-one
4-Androsten-17beta-ol-3-one
4-Androsten-3-one-17b-ol
4-androsten-17β-ol-3-one
4-androstene-17beta-ol-3-one
46923_FLUKA
46923_RIEDEL
58-22-0
7-beta-Hydroxyandrost-4-en-3-one
8-Iso-testosterone
9b,10a-Testosterone
9b-Testosterone
AA 2500
AC-14899
AC1L1LM0
Andriol
Andro
Andro 100
Andro L.A. 200
AndroGel
Androderm
Androderm (TN)
Androgel
Androgel (TN)
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
Andropatch
Andropository 200
Androsorb
Androst-4-en-17b-ol-3-one
Androst-4-en-17beta-ol-3-one
Androst-4-ene-17b-ol-3-one
Andrusol
Andryl 200
B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E
BIDD:ER0555
BIM-0061761.0001
Beta Testosterone
Bio-0678
Bio-T-Gel
C00535
CCRIS 574
CDB 111C
CHEBI:17347
CHEMBL386630
CID6013
CMC_13449
COL 1621
CP 601B
CPD000058344
Cristerona T
Cristerone T
D00075
D4-Androsten-17b-ol-3-one
DB00624
Dea No. 4000
Delatest
Delatestryl
Depo-Testadiol
Depo-Testosterone
Depo-Testosterone Cypionate
Depotest
EINECS 200-370-5
Epitestosteron
Everone 200
Geno-Cristaux Gremy
Geno-cristaux Gremy
Geno-cristaux gremy
HMS2052N11
HSDB 3398
Halotensin
Homosteron
Homosterone
 
Intrinsa
LMST02020002
LS-148813
LibiGel
Libigel
Lumitestosteron
MLS000563091
MLS001032098
MLS001306401
MLS002174283
Malerone
Malestrone
Malestrone (amps)
Malogen in Oil
Malogen, Aquaspension Injection
Malogen, aquaspension injection
Mertestate
Metandren
Methyltestosterone
MolPort-002-506-901
NCGC00091018-01
NSC 9700
Neo-Hombreol F
Neo-Testis
Neo-testis
Neotestis
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Perandren
Percutacrine Androgenique
Percutacrine androgenique
Primotest
Primoteston
Rac-17b-hydroxy-(13a)androst-4-en-3-one
Rac-17b-hydroxy-(8a)-androst-4-en-3-one
Rac-17b-hydroxy-(9b,10a)androst-4-en-3-one
Rac-17b-hydroxy-androst-4-en-3-one
Relibra
Retrotestosterone
S00309
S2033_Selleck
SAM001246921
SMR000058344
SMR001261453
Scheinpharm Testone-Cyp
Striant
Striant (TN)
Sustanon
Sustanone
Sustason 250
Synandrol F
T-Cypionate
T1500_SIGMA
T5411_FLUKA
T5411_SIGMA
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
Testim
Testim (TN)
Testobase
Testoderm
Testoderm Tts
Testogel
Testoject-50
Testolent
Testolin
Testopel Pellets
Testopropon
Testosteroid
Testosteron
Testosterona
Testosterona [INN-Spanish]
Testosterone
Testosterone (JAN/USP)
Testosterone Cypionate
Testosterone Enanthate
Testosterone Hydrate
Testosterone [Androgenic steroids, anabolic]
Testosterone [INN:BAN]
Testosterone and its esters
Testosterone hydrate
Testosterone solution
Testosteronum
Testosteronum [INN-Latin]
Testostosterone
Testostérone
Testoviron
Testoviron Schering
Testoviron T
Testoxyl
Testred
Testred Cypionate 200
Testrin-P.A
Testro AQ
Testro Aq
Testrone
Testryl
Tostrelle
Tostrex
Trans-Testosterone
UNII-3XMK78S47O
Viatrel
Virilon
Virilon IM
Virormone
Virosterone
ZINC06500184
beta testosterone
delta(sup 4)-Androsten-17(beta)-ol-3-one
delta4-Androsten-17beta-ol-3-one
delta4-androsten-17b-ol-3-one
testosterone
trans-Testosterone
13
RifampinapprovedPhase 433713292-46-15458213, 5381226
Synonyms:
1-b]furan-21-yl acetate
13292-46-1
3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin
3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV
3-(4-Methylpiperazinyliminomethyl)-rifamycin SV
3-(4-Methylpiperazinyliminomethyl)rifamycin SV
3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV
3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV
3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin
46713_FLUKA
46713_RIEDEL
62534-43-4
8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV
8-(4-Methylpiperazinyliminomethyl) rifamycin SV
8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin
8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv
8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv
83907_FLUKA
83907_SIGMA
8CI)
AZT + Rifampin
Abrifam
Archidyn
Arficin
Arzide
BA-41166E
BIDD:PXR0014
BPBio1_000561
BSPBio_000509
Ba 41166
Ba 41166/E
Benemicin
Benemycin
Bio-0621
C06688
C43H58N4O12
CAS-13292-46-1
CCRIS 551
CHEBI:28077
CHEBI:455936
CHEMBL180
CID5381226
CID5388984
CID5458213
CID5702112
CID6604339
CID6708473
CID6842115
CID6912767
CID6913622
CPD001906767
D00211
DB01045
DRG-0109
Dione 21-acetate
Dipicin
DivK1c_000550
Doloresum
EINECS 236-312-0
Eremfat
Famcin
Fenampicin
HMS1569J11
HMS1920P08
HMS2089F12
HMS2092G09
HMS501L12
HSDB 3181
KBio1_000550
KBio2_000919
KBio2_003487
KBio2_006055
KBio3_003018
KBioGR_001780
KBioSS_000919
L-5103
L-5103 Lepetit
LS-7689
MLS000028552
MLS001148237
MLS001333745
MolPort-000-767-051
MolPort-002-513-586
MolPort-003-666-281
MolPort-006-395-891
NCGC00016699-01
NCGC00017365-01
NCGC00018178-01
NCGC00022678-03
NCGC00022678-04
NCGC00022678-05
NCGC00160500-01
 
NCI60_000309
NINDS_000550
NSC 113926
NSC-113926
NSC113926
Piperine & Rifampicin
Prestwick0_000525
Prestwick1_000525
Prestwick2_000525
Prestwick3_000525
Prestwick_833
R-Cin
R/AMP
R0079
R3501_SIAL
R3501_SIGMA
R5777_SIGMA
R7382_SIGMA
RAMP
RFP
RMP
Ramp
Reserpine & Rifampicin
Rf
Rfamipicin
Rifa
Rifadin
Rifadin (TN)
Rifadin I.V
Rifadin I.V.
Rifadin IV
Rifadin Iv
Rifadin, Rimactane, Rifampicin, Rifampin
Rifadine
Rifagen
Rifaldazin
Rifaldazine
Rifaldin
Rifam
Rifamicin AMP
Rifamor
Rifampicin
Rifampicin & EEP
Rifampicin & Propolis
Rifampicin (JP15/INN)
Rifampicin SV
Rifampicin [INN:BAN:JAN]
Rifampicina
Rifampicina [INN-Spanish]
Rifampicine
Rifampicine [French]
Rifampicinum
Rifampicinum [INN-Latin]
Rifampin
Rifampin (USP)
Rifampin [USAN]
Rifamsolin
Rifamycin
Rifamycin AMP
Rifamycin Amp
Rifaprodin
Rifcin
Rifinah
Rifobac
Rifoldin
Rifoldine
Riforal
Rimactan
Rimactane
Rimactane (TN)
Rimactazid
Rimactin
Rimactizid
Rimazid
Rimycin
Rofact
S1764_Selleck
SAM002264646
SMR000058322
SMR000653525
SPBio_002430
SPECTRUM1500529
STK080143
Sinerdol
Spectrum3_001837
Spectrum4_001250
Spectrum5_002018
Spectrum_000439
TNP00313
Tubocin
UNII-VJT6J7R4TR
WLN: V1 WQ A&1 E&1 E1UN- AT6N DNTJ D1
nchembio884-comp4
rifampin
14Estradiol 17 beta-cypionatePhase 4, Phase 2, Phase 3, Phase 11283
15Antitussive AgentsPhase 4, Phase 1520
16Estradiol valeratePhase 4, Phase 2, Phase 3, Phase 11283979-32-8
17FluoroquinolonesPhase 4, Phase 2, Phase 3, Phase 1388
18Estradiol 3-benzoatePhase 4, Phase 2, Phase 3, Phase 11283
19Polyestradiol phosphatePhase 4, Phase 2, Phase 3, Phase 11283
20Topoisomerase InhibitorsPhase 4, Phase 2, Phase 3, Phase 14945
21AnalgesicsPhase 4, Phase 111287
22Central Nervous System DepressantsPhase 4, Phase 2, Phase 112806
23Chlorpheniramine, phenylpropanolamine drug combinationPhase 4, Phase 1616
24Norgestimate, ethinyl estradiol drug combinationPhase 4, Phase 2, Phase 3, Phase 1429
25Analgesics, OpioidPhase 4, Phase 13091
26Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14855
27Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 122776
28Contraceptives, Oral, CombinedPhase 4, Phase 2, Phase 3, Phase 1625
29Respiratory System AgentsPhase 4, Phase 14818
30Anti-Bacterial AgentsPhase 4, Phase 2, Phase 3, Phase 110884
31NarcoticsPhase 4, Phase 13486
32Contraceptives, OralPhase 4, Phase 2, Phase 3, Phase 11292
33Contraceptive AgentsPhase 4, Phase 2, Phase 3, Phase 11901
34Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 121402
35Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 212767
36HormonesPhase 4, Phase 213979
37Antimanic AgentsPhase 4790
38AnestheticsPhase 4, Phase 19001
39Anti-Arrhythmia AgentsPhase 4, Phase 2, Phase 12969
40ProgestinsPhase 4, Phase 2546
41AnticonvulsantsPhase 4, Phase 12620
42Antidepressive AgentsPhase 42666
43Hormone AntagonistsPhase 4, Phase 212778
44Lithium carbonatePhase 4232554-13-2
45GABA AgentsPhase 41622
46Neurotransmitter AgentsPhase 4, Phase 2, Phase 117734
47Psychotropic DrugsPhase 4, Phase 2, Phase 16279
48Tranquilizing AgentsPhase 4, Phase 2, Phase 14164
49Antipsychotic AgentsPhase 4, Phase 2, Phase 12359
50Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 310355

Interventional clinical trials:

(show top 50)    (show all 84)
idNameStatusNCT IDPhase
1Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care UnitUnknown statusNCT02025855Phase 4
2A Study of Aripiprazole (Abilify) in Patients With Bipolar ManiaCompletedNCT00261443Phase 4
3Genetics of QT Response to MoxifloxacinEnrolling by invitationNCT01936480Phase 4
4Imaging of Brain Amyloid Plaques in the Aging PopulationEnrolling by invitationNCT00950430Phase 4
5Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de PointesNot yet recruitingNCT02513940Phase 4
6Hemodynamic Responses to Tracheal Intubation Direct Laryngoscope and Videolaryngoscope in Elderly PatientsNot yet recruitingNCT02816775Phase 4
7Pediatric Lead Extractability and Survival Evaluation (PLEASE)TerminatedNCT00335036Phase 4
8Pharmacokinetics and Safety of MoxifloxacinTerminatedNCT01329250Phase 4
9Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIVCompletedNCT00035932Phase 3
10Registry of Unexplained Cardiac ArrestRecruitingNCT00292032Phase 3
11Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)RecruitingNCT02589782Phase 2, Phase 3
12Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3Active, not recruitingNCT02300558Phase 3
13Influence of Progesterone Administration on Drug-Induced QT Interval LengtheningCompletedNCT01929083Phase 2
14A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic PatientsCompletedNCT00845026Phase 2
15Long QT Syndrome Screening in NewbornsRecruitingNCT02412709Phase 2
16Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With RanolazineRecruitingNCT01728025Phase 2
17Efficacy Study of Sodium Channel Blocker in LQT3 PatientsRecruitingNCT01648205Phase 2
18Renal Nerve Stimulation and Renal Denervation in Patients With Sympathetic Ventricular ArrhythmiasRecruitingNCT02856373Phase 2
19Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of GastroparesisTerminatedNCT01323582Phase 2
20Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian VolunteersUnknown statusNCT02119091Phase 1
21Methadone Pharmacokinetics and Cardiac Effects in NewbornsUnknown statusNCT00715988Phase 1
22Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy AdultsCompletedNCT02365532Phase 1
23Study of the Effect of GS-6615 in Subjects With LQT-3CompletedNCT01849003Phase 1
24Effect of Eleclazine on QT, Safety, and Tolerability in Adults With Long QT2 SyndromeCompletedNCT02365506Phase 1
25Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic FunctionCompletedNCT02412098Phase 1
26Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal FunctionCompletedNCT02441829Phase 1
27Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy SubjectsCompletedNCT00316459Phase 1
28Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy VolunteersCompletedNCT00199225Phase 1
29Genetic Sources of Variability of the Adaptation of the Ventricular RepolarisationCompletedNCT00773201Phase 1
30Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current BlockCompletedNCT02308748Phase 1
31Selections of Subjects With Important Changes in Their Cardiac Repolarization Parameters for the Procurement of Skin and Blood SamplesCompletedNCT01338441Phase 1
32To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult SubjectsCompletedNCT01449188Phase 1
33Food and Insulin Effect on QT/QTC Interval of ECGCompletedNCT01642485Phase 1
34Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy SubjectsCompletedNCT01140425Phase 1
35QT/QTc Study of 2 Doses of ADASUVE®CompletedNCT01854710Phase 1
36A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult SubjectsCompletedNCT00789568Phase 1
37A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy VolunteersCompletedNCT01947920Phase 1
38Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran EtexilateCompletedNCT02171624Phase 1
39A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor ReceptorRecruitingNCT02365662Phase 1
40Effect of Potassium and Acetazolamide on People With Andersen-Tawil SyndromeTerminatedNCT00839501Phase 1
41Molecular Genetic Screening and Identification of Congenital Arrhythmogenic DiseasesUnknown statusNCT00221832
42The Effect of Erythromycin on Occurrence of Leaks From Cervical Esophageal-Gastric Anastomosis After Trans-Hiatal EsophagectomyUnknown statusNCT00373919
43Antiarrythmic Drugs - Long-term Follow-up in the Modern EraUnknown statusNCT01082055
44Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With EventsUnknown statusNCT01433848
45Typical Daily Experiences, Ischemia and Repolarization in Coronary Artery DiseaseUnknown statusNCT01531231
46The Long QT Syndrome in PregnancyCompletedNCT00488254
47Long QT Syndrome-Population Genetics and Cardiac StudiesCompletedNCT00005176
48QT-prolongation in Psychiatric HospitalsCompletedNCT02043925
49Drug Interactions With Risk of QT-prolongation in a General HospitalCompletedNCT02043912
50ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization PatientsCompletedNCT00399412

Search NIH Clinical Center for Long Qt Syndrome 1


Cochrane evidence based reviews: romano-ward syndrome

Genetic Tests for Long Qt Syndrome 1

About this section

Genetic tests related to Long Qt Syndrome 1:

id Genetic test Affiliating Genes
1 Romano-Ward Syndrome27
2 Long Qt Syndrome27 24
3 Long Qt Syndrome 127 24 KCNQ1

Anatomical Context for Long Qt Syndrome 1

About this section

MalaCards organs/tissues related to Long Qt Syndrome 1:

36
Heart, Testes, Skin, Liver, Brain, Lung

Publications for Long Qt Syndrome 1

About this section

Articles related to Long Qt Syndrome 1:

idTitleAuthorsYear
1
Impaired ion channel function related to a common KCNQ1 mutation - implications for risk stratification in long QT syndrome 1. (23000022)
2012
2
Bupivacaine destabilizes action potential duration in cellular and computational models of long QT syndrome 1. (22003215)
2011
3
Nicorandil normalizes prolonged repolarisation in the first transgenic rabbit model with Long-QT syndrome 1 both in vitro and in vivo. (20959120)
2011
4
Biophysical characterization of KCNQ1 P320 mutations linked to long QT syndrome 1. (19540844)
2010
5
A dominant negative isoform of the long QT syndrome 1 gene product. (9506986)
1998

Variations for Long Qt Syndrome 1

About this section

UniProtKB/Swiss-Prot genetic disease variations for Long Qt Syndrome 1:

70 (show all 123)
id Symbol AA change Variation ID SNP ID
1KCNQ1p.Gly168ArgVAR_001516rs179489
2KCNQ1p.Arg174CysVAR_001517rs199472696
3KCNQ1p.Ala178ProVAR_001518rs120074177
4KCNQ1p.Gly189ArgVAR_001519rs104894252
5KCNQ1p.Arg190GlnVAR_001520rs120074178
6KCNQ1p.Gly216ArgVAR_001521
7KCNQ1p.Val254MetVAR_001522rs120074179
8KCNQ1p.Glu261LysVAR_001523rs199472722
9KCNQ1p.Gly269AspVAR_001524rs120074194
10KCNQ1p.Leu273PheVAR_001525rs120074180
11KCNQ1p.Ala300ThrVAR_001526rs120074187
12KCNQ1p.Thr309ArgVAR_001529rs199472743
13KCNQ1p.Thr312IleVAR_001530rs120074182
14KCNQ1p.Ile313MetVAR_001531rs199472747
15KCNQ1p.Gly314SerVAR_001532rs120074184
16KCNQ1p.Tyr315SerVAR_001533rs74462309
17KCNQ1p.Asp317AsnVAR_001534rs199472751
18KCNQ1p.Pro320AlaVAR_001535rs199472753
19KCNQ1p.Gly325ArgVAR_001536rs199472756
20KCNQ1p.Ala341GluVAR_001538rs12720459
21KCNQ1p.Ala341ValVAR_001539rs12720459
22KCNQ1p.Leu342PheVAR_001540rs199472760
23KCNQ1p.Ala344ValVAR_001541rs199472763
24KCNQ1p.Gly345GluVAR_001542rs120074183
25KCNQ1p.Arg366ProVAR_001543rs199473410
26KCNQ1p.Ala371ThrVAR_001544rs199473412
27KCNQ1p.Arg555CysVAR_001545rs120074185
28KCNQ1p.Phe157CysVAR_008124rs199472690
29KCNQ1p.Tyr184SerVAR_008125rs199473397
30KCNQ1p.Gly345ArgVAR_008126rs199473471
31KCNQ1p.Ser373ProVAR_008127rs199472766
32KCNQ1p.Trp392ArgVAR_008128rs199472774
33KCNQ1p.Arg174HisVAR_008939rs199472697
34KCNQ1p.Asp242AsnVAR_008940rs199472712
35KCNQ1p.Trp248ArgVAR_008942rs199473459
36KCNQ1p.Leu250HisVAR_008943rs199472715
37KCNQ1p.Tyr281CysVAR_008945rs199472732
38KCNQ1p.Tyr315CysVAR_008946rs74462309
39KCNQ1p.Lys318AsnVAR_008947rs199472752
40KCNQ1p.Arg366TrpVAR_008948rs199473411
41KCNQ1p.Arg533TrpVAR_008949rs199472793
42KCNQ1p.Arg539TrpVAR_008950rs199472795
43KCNQ1p.Thr587MetVAR_008951rs120074189
44KCNQ1p.Gly589AspVAR_008952rs120074190
45KCNQ1p.Arg591HisVAR_008953rs199472814
46KCNQ1p.Leu353ProVAR_009180rs199473403
47KCNQ1p.Ala525ThrVAR_009181rs120074188
48KCNQ1p.Glu160LysVAR_009919rs199473453
49KCNQ1p.Ala178ThrVAR_009920rs120074177
50KCNQ1p.Ala194ProVAR_009922rs199472699
51KCNQ1p.Ser225LeuVAR_009923rs199473456
52KCNQ1p.Leu266ProVAR_009924rs199473460
53KCNQ1p.Gly269SerVAR_009925rs120074193
54KCNQ1p.Val310IleVAR_009926rs199472745
55KCNQ1p.Thr311IleVAR_009927rs199472746
56KCNQ1p.Ser349TrpVAR_009928rs199472765
57KCNQ1p.Arg366GlnVAR_009929rs199473410
58KCNQ1p.Thr391IleVAR_009930rs199473474
59KCNQ1p.Pro448ArgVAR_009931rs12720449
60KCNQ1p.Ser566PheVAR_009932rs199472804
61KCNQ1p.Arg583CysVAR_009933rs17221854
62KCNQ1p.Arg594GlnVAR_009934rs199472815
63KCNQ1p.Arg243CysVAR_010933rs199472713
64KCNQ1p.Val417MetVAR_010934rs267607197
65KCNQ1p.Lys362ArgVAR_048025rs12720458
66KCNQ1p.Ser277LeuVAR_065777rs199472730
67KCNQ1p.Pro320HisVAR_065778rs199473470
68KCNQ1p.Pro73ThrVAR_068287rs199472676
69KCNQ1p.Glu115GlyVAR_068288rs199472679
70KCNQ1p.Cys122TyrVAR_068289rs199472681
71KCNQ1p.Val133IleVAR_068290rs199473449
72KCNQ1p.Cys136PheVAR_068291rs199472686
73KCNQ1p.Ile204PheVAR_068292rs199472703
74KCNQ1p.Ile235AsnVAR_068293rs199472710
75KCNQ1p.Arg259CysVAR_068295rs199472719
76KCNQ1p.Arg259LeuVAR_068296rs199472720
77KCNQ1p.Leu273ArgVAR_068297rs199472727
78KCNQ1p.Tyr278HisVAR_068299rs199472731
79KCNQ1p.Glu290LysVAR_068300rs199473464
80KCNQ1p.Gly292AspVAR_068301rs199472736
81KCNQ1p.Arg293CysVAR_068302rs199472737
82KCNQ1p.Ala302ValVAR_068303rs193922365
83KCNQ1p.Trp304ArgVAR_068304rs199473466
84KCNQ1p.Gly314AspVAR_068305rs199472748
85KCNQ1p.Gly314ArgVAR_068306rs120074184
86KCNQ1p.Gly316ArgVAR_068307rs104894255
87KCNQ1p.Thr322AlaVAR_068308rs199472754
88KCNQ1p.Pro343SerVAR_068309rs199472762
89KCNQ1p.Ala344GluVAR_068310rs199472763
90KCNQ1p.Leu374HisVAR_068311rs199472767
91KCNQ1p.Arg380SerVAR_068312rs199472771
92KCNQ1p.Ser389TyrVAR_068313rs199472773
93KCNQ1p.Arg452TrpVAR_068314rs140452381
94KCNQ1p.Val524GlyVAR_068315rs199472790
95KCNQ1p.Lys526GluVAR_068316rs199472792
96KCNQ1p.Ser546LeuVAR_068317rs199473480
97KCNQ1p.Arg555HisVAR_068318rs199472800
98KCNQ1p.Ser566TyrVAR_068319rs199472804
99KCNQ1p.Ile567SerVAR_068320rs199472805
100KCNQ1p.Gly568ArgVAR_068321rs199472807
101KCNQ1p.Ala590ThrVAR_068322rs199472813
102KCNQ1p.Leu619MetVAR_068323rs199472819
103KCNQ1p.Gly626SerVAR_068324rs199472821
104KCNQ1p.Leu191ProVAR_074687rs199473401
105KCNQ1p.Arg243ProVAR_074688rs120074196
106KCNQ1p.Phe275SerVAR_074690rs199472729
107KCNQ1p.Gly306ValVAR_074691rs199472742
108KCNQ1p.Thr322MetVAR_074692rs199472755
109KCNQ1p.Lys557GluVAR_074693rs199472801
110KCNQ1p.Asn586AspVAR_074694rs199472812
111KCNQ1p.Ala46ThrVAR_074929rs199473671
112KCNQ1p.Ile204MetVAR_074952rs199473455
113KCNQ1p.Val215MetVAR_074954rs17215479
114KCNQ1p.Arg231CysVAR_074956rs199473457
115KCNQ1p.Arg231HisVAR_074957rs199472709
116KCNQ1p.Leu262ValVAR_074965rs199472723
117KCNQ1p.Gly272AspVAR_074967rs199472726
118KCNQ1p.Val280GluVAR_074971rs199473462
119KCNQ1p.Gly316GluVAR_074981rs199472749
120KCNQ1p.Pro343LeuVAR_074986rs199472761
121KCNQ1p.Gly350ArgVAR_074989rs199472824
122KCNQ1p.Phe351SerVAR_074990rs199473402
123KCNQ1p.Ile567ThrVAR_075023rs199472805

Clinvar genetic disease variations for Long Qt Syndrome 1:

5 (show all 87)
id Gene Variation Type Significance SNP ID Assembly Location
1RYR2NM_001035.2(RYR2): c.1298T> C (p.Leu433Pro)SNVPathogenicrs121918602GRCh37Chr 1, 237617696: 237617696
2KCNE1NM_000219.5(KCNE1): c.292C> T (p.Arg98Trp)SNVPathogenicrs199473362GRCh37Chr 21, 35821641: 35821641
3KCNE1NM_000219.5(KCNE1): c.253G> A (p.Asp85Asn)SNVLikely pathogenic, Pathogenic, risk factorrs1805128GRCh37Chr 21, 35821680: 35821680
4KCNH2NM_000238.3(KCNH2): c.1682C> T (p.Ala561Val)SNVLikely pathogenic, Pathogenicrs121912504GRCh37Chr 7, 150648799: 150648799
5KCNH2NM_000238.3(KCNH2): c.2255G> A (p.Arg752Gln)SNVLikely pathogenic, Pathogenicrs121912512GRCh37Chr 7, 150647399: 150647399
6KCNH2NM_000238.3(KCNH2): c.2738C> T (p.Ala913Val)SNVLikely pathogenic, Pathogenicrs77331749GRCh37Chr 7, 150644921: 150644921
7DSPNM_004415.3(DSP): c.3799C> T (p.Arg1267Ter)SNVLikely pathogenic, Pathogenicrs121912997GRCh37Chr 6, 7580222: 7580222
8CACNA1CNM_000719.6(CACNA1C): c.1216G> A (p.Gly406Arg)SNVPathogenicrs79891110GRCh37Chr 12, 2614110: 2614110
9KCNH2NM_000238.3(KCNH2): c.2900dupC (p.Pro968Alafs)duplicationPathogenicrs786204101GRCh37Chr 7, 150644759: 150644759
10KCNH2NM_000238.3(KCNH2): c.735_754dup20 (p.Arg252Profs)duplicationPathogenicrs794728425GRCh37Chr 7, 150655309: 150655328
11KCNH2NM_000238.3(KCNH2): c.2775dupG (p.Pro926Alafs)duplicationPathogenicrs794728455GRCh37Chr 7, 150644884: 150644884
12KCNH2NM_000238.3(KCNH2): c.3105_3112dupGGGCGACG (p.Val1038Glyfs)duplicationPathogenicrs794728470GRCh38Chr 7, 150947368: 150947375
13KCNQ1NM_000218.2(KCNQ1): c.1762A> T (p.Ile588Phe)SNVLikely pathogenic, Pathogenicrs794728536GRCh38Chr 11, 2778005: 2778005
14KCNQ1NM_000218.2(KCNQ1): c.364dupT (p.Cys122Leufs)duplicationPathogenicrs794728583GRCh37Chr 11, 2466692: 2466692
15SCN5ANM_198056.2(SCN5A): c.4850_4852delTCT (p.Phe1617del)deletionLikely pathogenic, Pathogenicrs749697698GRCh37Chr 3, 38593011: 38593013
16KCNQ1NM_000218.2(KCNQ1): c.557G> A (p.Gly186Asp)SNVPathogenicrs794728568GRCh38Chr 11, 2570707: 2570707
17KCNQ1NM_000218.2(KCNQ1): c.1051T> C (p.Phe351Leu)SNVPathogenicrs779383393GRCh38Chr 11, 2585230: 2585230
18KCNQ1NM_000218.2(KCNQ1): c.443delA (p.Tyr148Leufs)deletionPathogenicrs878854347GRCh38Chr 11, 2527984: 2527984
19KCNQ1NM_000218.2(KCNQ1): c.1733-1G> CSNVPathogenicrs878854348GRCh38Chr 11, 2777975: 2777975
20KCNQ1NM_000218.2(KCNQ1): c.758C> G (p.Ser253Cys)SNVPathogenicrs794728513GRCh38Chr 11, 2572087: 2572087
21KCNQ1NM_000218.2(KCNQ1): c.1480dupG (p.Glu494Glyfs)duplicationPathogenicrs878854349GRCh38Chr 11, 2662047: 2662047
22KCNQ1NM_000218.2(KCNQ1): c.1686-2A> GSNVPathogenicrs878854350GRCh38Chr 11, 2776984: 2776984
23KCNQ1NM_000218.2(KCNQ1): c.524_534dupTCTGGTCCGCC (p.Gly179Serfs)duplicationPathogenicrs879255588GRCh38Chr 11, 2570674: 2570684
24KCNQ1NM_000218.2(KCNQ1): c.349C> T (p.Pro117Ser)SNVLikely pathogenicrs886037906GRCh38Chr 11, 2445447: 2445447
25KCNQ1KCNQ1, 3-BP DELdeletionPathogenicChr na, -1: -1
26KCNQ1NM_000218.2(KCNQ1): c.532G> C (p.Ala178Pro)SNVPathogenicrs120074177GRCh37Chr 11, 2591912: 2591912
27KCNQ1NM_000218.2(KCNQ1): c.565G> A (p.Gly189Arg)SNVPathogenicrs104894252GRCh37Chr 11, 2591945: 2591945
28KCNQ1NM_000218.2(KCNQ1): c.916G> A (p.Gly306Arg)SNVPathogenicrs120074181GRCh37Chr 11, 2594211: 2594211
29KCNQ1NM_000218.2(KCNQ1): c.935C> T (p.Thr312Ile)SNVPathogenicrs120074182GRCh37Chr 11, 2604678: 2604678
30KCNQ1NM_000218.2(KCNQ1): c.569G> A (p.Arg190Gln)SNVPathogenicrs120074178GRCh37Chr 11, 2591949: 2591949
31KCNQ1NM_000218.2(KCNQ1): c.817C> T (p.Leu273Phe)SNVPathogenicrs120074180GRCh37Chr 11, 2594112: 2594112
32KCNQ1NM_000218.2(KCNQ1): c.1022C> A (p.Ala341Glu)SNVPathogenicrs12720459GRCh37Chr 11, 2604765: 2604765
33KCNQ1NM_000218.2(KCNQ1): c.1022C> T (p.Ala341Val)SNVPathogenicrs12720459GRCh37Chr 11, 2604765: 2604765
34KCNQ1NM_000218.2(KCNQ1): c.1034G> A (p.Gly345Glu)SNVPathogenicrs120074183GRCh37Chr 11, 2606443: 2606443
35KCNQ1NM_000218.2(KCNQ1): c.940G> A (p.Gly314Ser)SNVPathogenicrs120074184GRCh37Chr 11, 2604683: 2604683
36KCNQ1NM_000218.2(KCNQ1): c.1663C> T (p.Arg555Cys)SNVPathogenicrs120074185GRCh37Chr 11, 2797262: 2797262
37KCNQ1KCNQ1, 3-BP DEL, PHE339DELdeletionPathogenicChr na, -1: -1
38KCNQ1NM_000218.2(KCNQ1): c.211_219delGCCGCGCCC (p.Ala71_Pro73del)deletionPathogenicrs587776555GRCh38Chr 11, 2445309: 2445317
39KCNQ1NM_000218.2(KCNQ1): c.922-1G> CSNVPathogenicrs387906290GRCh37Chr 11, 2604664: 2604664
40KCNQ1NM_000218.2(KCNQ1): c.1032G> A (p.Ala344=)SNVPathogenicrs1800171GRCh37Chr 11, 2604775: 2604775
41KCNQ1NM_000218.2(KCNQ1): c.1760C> T (p.Thr587Met)SNVPathogenicrs120074189GRCh37Chr 11, 2799233: 2799233
42KCNQ1NM_000218.2(KCNQ1): c.1766G> A (p.Gly589Asp)SNVPathogenicrs120074190GRCh37Chr 11, 2799239: 2799239
43KCNQ1NM_000218.2(KCNQ1): c.350C> T (p.Pro117Leu)SNVPathogenicrs120074191GRCh37Chr 11, 2466678: 2466678
44KCNQ1NM_000218.2(KCNQ1): c.1747C> T (p.Arg583Cys)SNVPathogenic, risk factorrs17221854GRCh37Chr 11, 2799220: 2799220
45KCNQ1NM_000218.2(KCNQ1): c.805G> A (p.Gly269Ser)SNVPathogenicrs120074193GRCh37Chr 11, 2594100: 2594100
46KCNQ1NM_000218.2(KCNQ1): c.806G> A (p.Gly269Asp)SNVPathogenicrs120074194GRCh37Chr 11, 2594101: 2594101
47KCNQ1NM_000218.2(KCNQ1): c.760G> A (p.Val254Met)SNV, HaplotypeLikely pathogenic, Pathogenicrs120074179GRCh37Chr 11, 2593319: 2593319
48KCNQ1NM_000218.2(KCNQ1): c.905C> T (p.Ala302Val)SNVPathogenicrs193922365GRCh37Chr 11, 2594200: 2594200
49KCNQ1NM_000218.2(KCNQ1): c.613G> A (p.Val205Met)SNVPathogenicrs151344631GRCh37Chr 11, 2592563: 2592563
50KCNQ1NM_000218.2(KCNQ1): c.1033G> C (p.Gly345Arg)SNVPathogenicrs199473471GRCh37Chr 11, 2606442: 2606442
51KCNQ1NM_000218.2(KCNQ1): c.1096C> T (p.Arg366Trp)SNVLikely pathogenic, Pathogenicrs199473411GRCh37Chr 11, 2606505: 2606505
52KCNQ1NM_000218.2(KCNQ1): c.1615C> T (p.Arg539Trp)SNVPathogenicrs199472795GRCh37Chr 11, 2797214: 2797214
53KCNQ1NM_000218.2(KCNQ1): c.1637C> T (p.Ser546Leu)SNVPathogenicrs199473480GRCh37Chr 11, 2797236: 2797236
54KCNQ1NM_000218.2(KCNQ1): c.1700T> C (p.Ile567Thr)SNVPathogenicrs199472805GRCh37Chr 11, 2798230: 2798230
55KCNQ1NM_000218.2(KCNQ1): c.1703G> C (p.Gly568Ala)SNVPathogenicrs199472806GRCh37Chr 11, 2798233: 2798233
56KCNQ1NM_000218.2(KCNQ1): c.1781G> A (p.Arg594Gln)SNVLikely pathogenic, Pathogenicrs199472815GRCh37Chr 11, 2799254: 2799254
57KCNQ1NM_000218.2(KCNQ1): c.1893dupC (p.Arg632Glnfs)duplicationPathogenicrs397508105GRCh37Chr 11, 2869095: 2869095
58KCNQ1NM_000218.2(KCNQ1): c.502G> A (p.Gly168Arg)SNVPathogenicrs179489GRCh37Chr 11, 2591882: 2591882
59KCNQ1NM_000218.2(KCNQ1): c.532G> A (p.Ala178Thr)SNVLikely pathogenic, Pathogenicrs120074177GRCh37Chr 11, 2591912: 2591912
60KCNQ1NM_000218.2(KCNQ1): c.533delCinsGG (p.Ala178Glyfs)indelPathogenicrs397508115GRCh37Chr 11, 2591913: 2591913
61KCNQ1NM_000218.2(KCNQ1): c.567dupG (p.Arg190Alafs)duplicationPathogenicrs397508117GRCh37Chr 11, 2591947: 2591947
62KCNQ1NM_000218.2(KCNQ1): c.573_577delGCGCT (p.Arg192Cysfs)deletionPathogenicrs397508118GRCh37Chr 11, 2591953: 2591957
63KCNQ1NM_000218.2(KCNQ1): c.585delG (p.Lys196Serfs)deletionLikely pathogenic, Pathogenicrs397508120GRCh37Chr 11, 2591965: 2591965
64KCNQ1NM_000218.2(KCNQ1): c.691C> T (p.Arg231Cys)SNVLikely pathogenic, Pathogenicrs199473457GRCh37Chr 11, 2593250: 2593250
65KCNQ1NM_000218.2(KCNQ1): c.692G> A (p.Arg231His)SNVPathogenicrs199472709GRCh37Chr 11, 2593251: 2593251
66KCNQ1NM_000218.2(KCNQ1): c.727C> T (p.Arg243Cys)SNVPathogenicrs199472713GRCh37Chr 11, 2593286: 2593286
67KCNQ1NM_000218.2(KCNQ1): c.775C> T (p.Arg259Cys)SNVLikely pathogenic, Pathogenicrs199472719GRCh37Chr 11, 2593334: 2593334
68KCNQ1NM_000218.2(KCNQ1): c.797T> C (p.Leu266Pro)SNVLikely pathogenic, Pathogenicrs199473460GRCh37Chr 11, 2594092: 2594092
69KCNQ1NM_000218.2(KCNQ1): c.815G> A (p.Gly272Asp)SNVPathogenicrs199472726GRCh37Chr 11, 2594110: 2594110
70KCNQ1NM_000218.2(KCNQ1): c.824_826delTCT (p.Phe275del)deletionPathogenicrs397508126GRCh37Chr 11, 2594119: 2594121
71KCNQ1NM_000218.2(KCNQ1): c.828_830delCTC (p.Ser277del)deletionPathogenicrs397508127GRCh37Chr 11, 2594123: 2594125
72KCNQ1NM_000218.2(KCNQ1): c.830C> T (p.Ser277Leu)SNVLikely pathogenic, Pathogenicrs199472730GRCh37Chr 11, 2594125: 2594125
73KCNQ1NM_000218.2(KCNQ1): c.965C> T (p.Thr322Met)SNVLikely pathogenic, Pathogenicrs199472755GRCh37Chr 11, 2604708: 2604708
74KCNQ1NM_000218.2(KCNQ1): c.1597C> T (p.Arg533Trp)SNVPathogenicrs199472793GRCh37Chr 11, 2797196: 2797196
75KCNQ1NM_000218.2(KCNQ1): c.625T> C (p.Ser209Pro)SNVPathogenicrs199472705GRCh37Chr 11, 2592575: 2592575
76KCNH2NM_000238.3(KCNH2): c.1801G> A (p.Gly601Ser)SNVPathogenicrs199472936GRCh37Chr 7, 150648680: 150648680
77KCNH2NM_000238.3(KCNH2): c.1810G> A (p.Gly604Ser)SNVPathogenicrs199473522GRCh37Chr 7, 150648671: 150648671
78KCNH2NM_000238.3(KCNH2): c.1847A> G (p.Tyr616Cys)SNVLikely pathogenic, Pathogenicrs199472946GRCh37Chr 7, 150648634: 150648634
79KCNH2NM_000238.3(KCNH2): c.2467C> T (p.Arg823Trp)SNVLikely pathogenic, Pathogenicrs199473538GRCh37Chr 7, 150646069: 150646069
80KCNH2NM_000238.3(KCNH2): c.916G> C (p.Gly306Arg)SNVLikely pathogenic, Pathogenicrs199472884GRCh37Chr 7, 150655147: 150655147
81SCN5ANM_000335.4(SCN5A): c.1231G> A (p.Val411Met)SNVPathogenicrs72549410GRCh37Chr 3, 38647549: 38647549
82KCNJ5NM_000890.3(KCNJ5): c.1159G> C (p.Gly387Arg)SNVPathogenicrs199830292GRCh37Chr 11, 128786525: 128786525
83CALM2NM_001743.5(CALM2): c.293A> G (p.Asn98Ser)SNVLikely pathogenic, Pathogenicrs398124647GRCh37Chr 2, 47388990: 47388990
84CALM2NM_001743.5(CALM2): c.293A> T (p.Asn98Ile)SNVLikely pathogenic, Pathogenicrs398124647GRCh37Chr 2, 47388990: 47388990
85CALM2NM_001743.5(CALM2): c.396T> G (p.Asp132Glu)SNVLikely pathogenic, Pathogenicrs398124648GRCh37Chr 2, 47388887: 47388887
86CALM2NM_001743.5(CALM2): c.400G> C (p.Asp134His)SNVLikely pathogenic, Pathogenicrs398124650GRCh37Chr 2, 47388883: 47388883
87CALM2NM_001743.5(CALM2): c.407A> C (p.Gln136Pro)SNVLikely pathogenic, Pathogenicrs398124649GRCh37Chr 2, 47388876: 47388876

Copy number variations for Long Qt Syndrome 1 from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
14830911110700000GainLong-qt syndrome
2221890213474085734806443Genomic rearrangementKCNE1Long-qt syndrome
3221892213465819234665310Genomic rearrangemen tKCNE2Long-qt syndrome
42218947147500000154700000Genomic rearrangementKCNH2Long-qt syndrome
52218961124227962826916Genomic rearrangemen tKCNQ1Long-qt syndrome
622189833856455638666167Genomic rearrangemen tSCN5ALong-qt syndrome
72219307147900000152600000LossLong-qt syndrome

Expression for genes affiliated with Long Qt Syndrome 1

About this section
Search GEO for disease gene expression data for Long Qt Syndrome 1.

Pathways for genes affiliated with Long Qt Syndrome 1

About this section

Pathways related to Long Qt Syndrome 1 according to GeneCards Suite gene sharing:

(show all 22)
idSuper pathwaysScoreTop Affiliating Genes
110.3CALM1, CALM2
210.2ANK2, SCN4B, SCN5A
310.2CALM1, CALM2, CAV3
410.2CALM1, CALM2, NOS1AP
5
Show member pathways
10.1CACNA1C, CALM1, CALM2, RYR2
6
Show member pathways
10.1CACNA1C, CALM1, CALM2, RYR2
710.1CACNA1C, CALM1, CALM2, RYR2
810.1CACNA1C, CALM1, CALM2, KCNJ2
9
Show member pathways
10.0CALM1, CALM2, KCNE2, KCNJ2, KCNQ1
10
Show member pathways
10.0CACNA1C, CALM1, CALM2, KCNJ5, RYR2
11
Show member pathways
10.0CACNA1C, CALM1, CALM2, RYR2, SNTA1
12
Show member pathways
9.9CACNA1C, CALM1, CALM2, KCNJ5, SCN4B, SCN5A
13
Show member pathways
9.9KCND2, KCND3, KCNH2, KCNJ2, KCNJ5, KCNQ1
14
Show member pathways
9.9CACNA1C, CALM1, CALM2, KCNJ2, KCNJ5, RYR2
15
Show member pathways
9.8AKAP9, ANK2, CACNA1C, CALM1, CALM2, SCN4B
16
Show member pathways
9.8CACNA1C, CALM1, CALM2, KCNE1, KCNQ1, RYR2
179.8CAV3, KCNH2, KCNQ1, NOS1AP, RYR2, SCN4B
18
Show member pathways
9.6AKAP9, CALM1, CALM2, KCND2, KCND3, KCNH2
19
Show member pathways
9.6CACNA1C, CALM1, CALM2, KCND2, KCNJ2, KCNJ5
209.4AKAP9, CACNA1C, CALM1, CALM2, KCND2, KCND3
219.3ANK2, CACNA1C, DSP, KCND3, KCNE1, KCNE2
22
Show member pathways
9.1AKAP9, CACNA1C, CALM1, CALM2, CAV3, KCND2

GO Terms for genes affiliated with Long Qt Syndrome 1

About this section

Cellular components related to Long Qt Syndrome 1 according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1L-type voltage-gated calcium channel complexGO:199045411.1CACNA1C, NOS1AP
2caveolaGO:000590111.0CAV3, NOS1AP, SCN5A
3calcium channel complexGO:003470411.0CALM1, CALM2, RYR2
4membrane raftGO:004512110.9ANK2, CAV3, KCNE1, KCNQ1
5voltage-gated sodium channel complexGO:000151810.8SCN4B, SCN5A
6sarcomereGO:003001710.8CALM1, CALM2, RYR2
7intercalated discGO:001470410.7ANK2, CAV3, DSP, KCNJ2, SCN4B, SCN5A
8sarcolemmaGO:004238310.5ANK2, CAV3, KCND3, NOS1AP, SCN5A, SNTA1
9T-tubuleGO:003031510.5ANK2, CAV3, KCNJ2, KCNJ5, NOS1AP, SCN5A
10voltage-gated potassium channel complexGO:000807610.0AKAP9, CALM1, CALM2, KCND2, KCND3, KCNE1
11Z discGO:00300189.8ANK2, CACNA1C, CAV3, KCNE1, NOS1AP, RYR2
12plasma membraneGO:00058869.5ANK2, CACNA1C, CALM1, CALM2, CAV3, DSP

Biological processes related to Long Qt Syndrome 1 according to GeneCards Suite gene sharing:

(show top 50)    (show all 60)
idNameGO IDScoreTop Affiliating Genes
1atrial cardiac muscle cell action potentialGO:008601411.0ANK2, KCNQ1
2AV node cell action potentialGO:008601611.0SCN4B, SCN5A
3membrane depolarization during SA node cell action potentialGO:008604611.0ANK2, SCN5A
4negative regulation of delayed rectifier potassium channel activityGO:190226011.0KCNE1, KCNE2
5potassium ion export across plasma membraneGO:009762311.0KCNH2, KCNQ1
6cellular response to epinephrine stimulusGO:007187211.0KCNQ1, RYR2
7negative regulation of potassium ion transmembrane transportGO:190138011.0CAV3, KCNH2
8membrane depolarization during AV node cell action potentialGO:008604511.0CACNA1C, SCN5A
9calcium ion transport into cytosolGO:006040211.0CACNA1C, RYR2
10positive regulation of potassium ion transmembrane transporter activityGO:190101811.0AKAP9, ANK2
11negative regulation of peptidyl-threonine phosphorylationGO:001080111.0CALM1, CALM2
12cell communication by electrical coupling involved in cardiac conductionGO:008606411.0CACNA1C, RYR2
13negative regulation of ryanodine-sensitive calcium-release channel activityGO:006031511.0CALM1, CALM2
14positive regulation of cyclic nucleotide metabolic processGO:003080111.0CALM1, CALM2
15positive regulation of cyclic-nucleotide phosphodiesterase activityGO:005134311.0CALM1, CALM2
16positive regulation of phosphoprotein phosphatase activityGO:003251611.0CALM1, CALM2
17positive regulation of ryanodine-sensitive calcium-release channel activityGO:006031611.0CALM1, CALM2
18cellular response to drugGO:003569011.0KCNE2, KCNH2, KCNQ1
19regulation of atrial cardiac muscle cell membrane repolarizationGO:006037210.9KCNQ1, SCN5A
20cellular response to cAMPGO:007132010.9AKAP9, KCNE1, KCNQ1
21regulation of delayed rectifier potassium channel activityGO:190225910.9KCNE1, KCNE2
22regulation of calcium ion transmembrane transporter activityGO:190101910.9ANK2, CAV3
23regulation of atrial cardiac muscle cell action potentialGO:009891010.9ANK2, RYR2
24regulation of cardiac muscle contraction by calcium ion signalingGO:001088210.9ANK2, RYR2
25regulation of cell communication by electrical coupling involved in cardiac conductionGO:190184410.9CALM1, CALM2
26detection of calcium ionGO:000551310.9CALM1, CALM2, RYR2
27membrane repolarization during ventricular cardiac muscle cell action potentialGO:009891510.9KCNE1, KCNE2, KCNH2, KCNQ1
28potassium ion importGO:001010710.9KCNE2, KCNJ2, KCNJ5
29positive regulation of nitric-oxide synthase activityGO:005100010.9CALM1, CALM2, NOS1AP
30membrane repolarization during cardiac muscle cell action potentialGO:008601310.8KCNE1, KCNH2, KCNJ2, KCNQ1
31membrane repolarizationGO:008600910.8KCND3, KCNE1, KCNE2, KCNQ1
32regulation of cardiac muscle cell contractionGO:008600410.8ANK2, KCNJ2, SCN5A
33regulation of sodium ion transmembrane transportGO:190230510.8SCN5A, SNTA1
34regulation of SA node cell action potentialGO:009890710.8ANK2, RYR2
35muscle contractionGO:000693610.8CALM1, CALM2, CAV3, SNTA1
36potassium ion transportGO:000681310.8KCND3, KCNJ2, KCNJ5
37membrane depolarization during cardiac muscle cell action potentialGO:008601210.8CACNA1C, KCNJ2, SCN4B, SCN5A
38regulation of potassium ion transmembrane transportGO:190137910.8KCNE1, KCNE2, KCNH2
39regulation of sodium ion transmembrane transporter activityGO:200064910.8CAV3, SCN4B
40cardiac muscle contractionGO:006004810.8KCNH2, KCNQ1, RYR2, SCN4B, SCN5A
41membrane repolarization during action potentialGO:008601110.8KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1
42regulation of ventricular cardiac muscle cell membrane depolarizationGO:006037310.8CAV3, SCN5A
43regulation of high voltage-gated calcium channel activityGO:190184110.7CALM1, CALM2, NOS1AP
44potassium ion exportGO:007143510.7KCND3, KCNE1, KCNE2, KCNH2, KCNQ1
45regulation of nitric-oxide synthase activityGO:005099910.7CALM1, CALM2, NOS1AP
46positive regulation of potassium ion transmembrane transportGO:190138110.7KCNE1, KCNH2, KCNJ2, KCNQ1, NOS1AP
47SA node cell action potentialGO:008601510.7ANK2, SCN5A
48cardiac muscle cell action potential involved in contractionGO:008600210.6CACNA1C, KCNE1, KCNE2, KCNJ2, SCN4B, SCN5A
49regulation of cardiac muscle contractionGO:005511710.6ANK2, CALM1, CALM2, CAV3, RYR2
50sarcoplasmic reticulum calcium ion transportGO:007029610.6ANK2, RYR2

Molecular functions related to Long Qt Syndrome 1 according to GeneCards Suite gene sharing:

(show all 26)
idNameGO IDScoreTop Affiliating Genes
1adenylate cyclase bindingGO:000817911.1CALM1, CALM2
2inositol-1,4,5-trisphosphate 3-kinase activityGO:000844011.1CALM1, CALM2
3N-terminal myristoylation domain bindingGO:003199711.1CALM1, CALM2
4nitric-oxide synthase regulator activityGO:003023511.1CALM1, CALM2
5G-protein activated inward rectifier potassium channel activityGO:001546711.1KCNJ2, KCNJ5
6potassium channel regulator activityGO:001545911.1AKAP9, KCNE1, KCNE2
7A-type (transient outward) potassium channel activityGO:000525011.1KCND2, KCND3
8protein kinase A catalytic subunit bindingGO:003423611.0KCNQ1, RYR2
9inward rectifier potassium channel activityGO:000524211.0KCNE2, KCNH2, KCNJ2, KCNJ5
10protein kinase A regulatory subunit bindingGO:003423710.9AKAP9, KCNQ1, RYR2
11protein phosphatase activator activityGO:007254210.9CALM1, CALM2
12calmodulin bindingGO:000551610.9CACNA1C, KCNQ1, RYR2, SCN5A, SNTA1
13thioesterase bindingGO:003199610.8CALM1, CALM2
14titin bindingGO:003143210.8CALM1, CALM2
15type 3 metabotropic glutamate receptor bindingGO:003180010.8CALM1, CALM2
16delayed rectifier potassium channel activityGO:000525110.8KCND2, KCND3, KCNE1, KCNE2, KCNH2, KCNQ1
17nitric-oxide synthase bindingGO:005099810.7CALM1, CALM2, CAV3, NOS1AP, SCN5A, SNTA1
18sodium channel regulator activityGO:001708010.7CAV3, SCN4B, SNTA1
19scaffold protein bindingGO:009711010.7DSP, KCNH2, KCNQ1, SCN5A
20protein kinase bindingGO:001990110.6ANK2, CALM1, CALM2, RYR2, SCN5A
21voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationGO:008600810.4KCNE1, KCNH2, KCNJ2, KCNQ1
22voltage-gated potassium channel activityGO:000524910.4KCND2, KCNE1, KCNE2, KCNH2, KCNQ1
23voltage-gated sodium channel activity involved in cardiac muscle cell action potentialGO:008600610.3SCN4B, SCN5A
24voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationGO:190228210.3KCNE1, KCNE2, KCNH2, KCNQ1
25ion channel bindingGO:004432510.2AKAP9, ANK2, CALM1, CALM2, CAV3, KCND3
26protein bindingGO:00055159.4AKAP9, ANK2, CACNA1C, CALM1, CALM2, CAV3

Sources for Long Qt Syndrome 1

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet